Comparative effectiveness of erythropoietin alpha and beta in hemodialysis patients: a single-center prospective observational study.

Autor: Ahsan MN; Department of Nephrology, Dow University of Health Sciences, Karachi, Pakistan., Asif N; Department of Nephrology, Liaquat National Hospital and Medical College, Karachi, Pakistan., Khanzada SW; Department of Nephrology, Liaquat National Hospital and Medical College, Karachi, Pakistan., Asghar MS; Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan., Yasmin F; Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan., Khalid F; Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan., Fareed S; Department of Nephrology, Dow University of Health Sciences, Karachi, Pakistan., Irshad SG; Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Jazyk: angličtina
Zdroj: Journal of community hospital internal medicine perspectives [J Community Hosp Intern Med Perspect] 2021 Nov 15; Vol. 11 (6), pp. 782-786. Date of Electronic Publication: 2021 Nov 15 (Print Publication: 2021).
DOI: 10.1080/20009666.2021.1983980
Abstrakt: Background and Objectives: Anemia is a prevalent complication endured by patients with chronic renal disease. Renal anemia also leads to the development of cardio-vascular complications. Epoetin alpha and beta are recombinant human erythropoietin prioritized for managing anemia in hemodialysis patients. The current study aimed to compare the therapeutic efficacy of both erythropoietin alpha and erythropoietin beta in treating renal anemia.
Materials and Methods: This prospective observational study was conducted in a Renal Dialysis Centre at a tertiary care Hospital of Karachi, Pakistan for a period of 3 months. The two erythropoietin products used were human recombinant erythropoietin alpha (Tropin®) and erythropoietin beta (Recormon®). Both groups were age-matched, BMI, eGFR, gender, and comorbidities like diabetes and hypertension were indifferent. The comparative analysis was performed after the completion of 3 months.
Results: A total of 94 participants were included in the analysis, 54 in group A and 40 in group B. Mean albumin, urea, creatinine, ferritin, iron, and transferrin saturation at inclusion were statistically insignificant, TIBC was higher in group A (p = 0.005) and CRP levels were slightly higher in group B (p = 0.050). There was significant improvement in Hb level (p = 0.025), PCV (p = 0.001), and RBC count (p = 0.007) in group B. While in group A, there was significantly increased MCV (p = 0.005) and MCHC (p = 0.002). In intention to treat analysis, 22.2% of subjects in group A and 40.0% in group B reached desired Hb levels of ≥11 g/l after 3 months.
Conclusion: In our assessment of hemodialysis patients, erythropoietin beta was found more effective than erythropoietin alpha.
Competing Interests: The authors declare that they have no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article.
(© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of Greater Baltimore Medical Center.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje